What is Epistem?
Epistem is a specialized provider of innovative models, platforms, and services designed to enhance decision-making across drug discovery, development, and early clinical pipelines. Serving a clientele of over 200 pharmaceutical and biotechnology firms, Epistem offers comprehensive preclinical and clinical services with a particular emphasis on oncology, inflammatory diseases, and gastrointestinal conditions. The company operates GCLP-accredited laboratories equipped for a variety of assays, including histology, gene expression analysis, and DNA genotyping. Epistem's strength lies in its seasoned technical team, capable of developing custom protocols and delivering bespoke services to precisely meet unique research requirements.
How much funding has Epistem raised?
Epistem has raised a total of $9.5M across 1 funding round:
Private Equity
$9.5M
Private Equity (2016): $9.5M, investors not publicly disclosed
What's next for Epistem?
The recent major strategic investment into Epistem signals a pivotal moment for the company, likely enabling accelerated expansion of its service offerings and technological capabilities. This capital infusion is expected to bolster its position in supporting critical research for pharmaceutical and biotechnology clients, particularly in complex therapeutic areas. Epistem's focus on oncology and inflammatory diseases, coupled with its advanced laboratory services, positions it for continued growth and deeper integration into the drug development ecosystem.
See full Epistem company page
